News and Events

Relievant Medsystems Announces First Patient Enrollment in the INTRACEPT Clinical Study

Steven R. Garfin, M.D., Named Principal Investigator

October 24, 2017 – SUNNYVALE, Calif.

Relievant Medsystems, a privately held medical device company that has developed the Intracept® Procedure, a minimally invasive and clinically proven approach for the treatment of chronic low back pain, announced today the enrollment of the first patient in the INTRACEPT study – a Level I, prospective, randomized clinical trial...

Relievant Medsystems Names Ray M. Baker, M.D. as Chief Medical Officer

Past President of North American Spine Society Joins Executive Management Team

October 17, 2017 – SUNNYVALE, Calif.

Relievant Medsystems, a privately held medical device company that has developed the Intracept® Procedure, a minimally invasive and clinically proven approach for the treatment of chronic low back pain, today announced the appointment of Ray M. Baker, M.D., as Chief Medical Officer. Dr. Baker will report to Relievant’s Chief Executive...

Relievant Medsystems, Inc. Secures $36 Million in Equity Financing for INTRACEPT® Clinical Development and Commercial Launch Preparation

October 11, 2016 — Redwood City, CA

Relievant Medsystems, Inc. Receives FDA 510(k) Clearance for INTRACEPT® for the Relief of Chronic Low Back Pain

Landmark Level 1 Clinical Study Provides Compelling Data for New Therapy

July 21, 2016 — Redwood City, CA

Relievant Medsystems, Inc., a privately held medical device company pioneering the therapy of nerve ablation within vertebral bodies for the treatment of chronic low back pain, announced today that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the INTRACEPT® Intraosseous Nerve Ablation System.

The INTRACEPT System is...

Relievant Medsystems Appoints Alex M. DiNello as President and Chief Executive Officer

DiNello Brings Significant Spine and Commercialization Experience

August 23, 2011 — Redwood City, CA — (PRNewswire)

Relievant Medsystems, Inc., today announced the appointment of Alex DiNello to the position of president and chief executive officer and as a member of the company’s board of directors. The Company recently received FDA approval of an Investigational Device Exemption (IDE) to begin its SMART pivotal trial. The Surgical...